Multiple studies have shown that small structural differences in HSPG2 across diseases have antagonistic effects on tumor formation and metastasis; intact perlecan promotes the development of a vascular supply that supports tumor cell proliferation and the development of a variety of cancers, whereas bioactive perlecan fragments inhibit tumor development by targeting its vascular supply (22, 23). This evidence concerns the gene HSPG2 and cancer.